Compare Stocks

Date Range: 

 Vor BiopharmaConnect BiopharmaBolt BiotherapeuticsOxford BiomedicaKinnate Biopharma
SymbolNYSE:VORNASDAQ:CNTBNASDAQ:BOLTLON:OXBNASDAQ:KNTE
Price Information
Current Price$24.53$15.53$22.85GBX 1,024.20$24.68
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.71.30.81.7
Analysis Score4.33.53.51.33.5
Community Score3.55.02.82.55.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$48.20$29.50$41.00GBX 1,003.33$52.00
% Upside from Price Target96.49% upside89.95% upside79.43% upside-2.04% downside110.70% upside
Trade Information
Market Cap$910.75 million$893.04 million$830.10 million£843.83 million$1.07 billion
BetaN/AN/AN/AN/AN/A
Average Volume241,259156,632269,490158,415190,792
Sales & Book Value
Annual RevenueN/AN/AN/A£87.73 millionN/A
Price / SalesN/AN/AN/A9.62N/A
CashflowN/AN/AN/AGBX 56.34 per shareN/A
Price / CashN/AN/AN/A18.18N/A
Book ValueN/AN/AN/AGBX 137 per shareN/A
Price / BookN/AN/AN/A0.07N/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AN/AGBX (7.80)N/A
Trailing P/E Ratio0.000.000.00N/A0.00
Forward P/E RatioN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A12.28%N/A
Current RatioN/AN/AN/A2.06%N/A
Quick RatioN/AN/AN/A1.88%N/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees88626567331
Shares Outstanding37.13 million57.50 million36.33 million82.41 million43.49 million
Next Earnings Date8/5/2021 (Estimated)N/A6/30/2021 (Estimated)N/A7/5/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Kinnate Biopharma Inc. Forecasted to Earn Q1 2021 Earnings of ($0.41) Per Share (NASDAQ:KNTE)Kinnate Biopharma Inc. Forecasted to Earn Q1 2021 Earnings of ($0.41) Per Share (NASDAQ:KNTE)
americanbankingnews.com - May 6 at 7:12 AM
Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of DirectorsKinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors
finance.yahoo.com - April 30 at 10:15 AM
Orbimed Advisors reduced stake in Graybug Vision, Inc.Orbimed Advisors reduced stake in Graybug Vision, Inc.
investing.com - April 20 at 7:44 PM
Kinnate Biopharma Inc. (NASDAQ:KNTE) Sees Large Growth in Short InterestKinnate Biopharma Inc. (NASDAQ:KNTE) Sees Large Growth in Short Interest
americanbankingnews.com - April 18 at 4:52 PM
Kinnate Biopharma Inc (KNTE)Kinnate Biopharma Inc (KNTE)
investing.com - April 14 at 4:19 AM
Kinnate Biopharma Inc. Reports Full Year 2020 Financial ResultsKinnate Biopharma Inc. Reports Full Year 2020 Financial Results
finance.yahoo.com - March 29 at 7:44 PM
Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® IndexKinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index
finance.yahoo.com - March 19 at 4:48 PM
Were Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash WiselyWe're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely
finance.yahoo.com - March 3 at 8:51 AM
Kinnate Biopharma Inc. to Participate in Upcoming Investor ConferencesKinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 11 at 6:15 PM
Kinnate Biopharma, Inc. (KNTE)Kinnate Biopharma, Inc. (KNTE)
realmoney.thestreet.com - December 30 at 10:14 PM
Why SVB Leerink Is Bullish On Kinnate BiopharmaWhy SVB Leerink Is Bullish On Kinnate Biopharma
markets.businessinsider.com - December 28 at 3:44 PM
Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the ...Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the ...
apnews.com - December 8 at 4:35 PM
Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional SharesKinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
benzinga.com - December 7 at 11:06 PM
Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesKinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - December 7 at 6:06 PM
Kinnate Biopharma IncKinnate Biopharma Inc
reuters.com - December 6 at 4:48 PM
Kinnate Biopharma Inc. (KNTE)Kinnate Biopharma Inc. (KNTE)
in.finance.yahoo.com - December 4 at 10:17 PM
Biotech IPOs Of Seer, Silverback Jump As Trading Gets UnderwayBiotech IPOs Of Seer, Silverback Jump As Trading Gets Underway
finance.yahoo.com - December 4 at 5:16 PM
Kinnate Biopharma Announces Pricing of Initial Public OfferingKinnate Biopharma Announces Pricing of Initial Public Offering
apnews.com - December 3 at 10:28 PM
Oncology biotech Kinnate Biopharma ups proposed deal size by 25% ahead of $213 million IPOOncology biotech Kinnate Biopharma ups proposed deal size by 25% ahead of $213 million IPO
nasdaq.com - December 3 at 10:28 PM
IPO Alert: Kinnate BiopharmaIPO Alert: Kinnate Biopharma
markets.businessinsider.com - December 3 at 10:28 PM
Kinnate Biopharma to offer 11.5 million shares in planned IPO, priced at $18 to $19 eachKinnate Biopharma to offer 11.5 million shares in planned IPO, priced at $18 to $19 each
marketwatch.com - December 3 at 10:28 PM
Kinnate Biopharma upsizes IPO and prices above range at $20 a shareKinnate Biopharma upsizes IPO and prices above range at $20 a share
msn.com - December 3 at 10:28 PM
Oncology biotech Kinnate Biopharma prices further upsized IPO at $20, above the upwardly revised rangeOncology biotech Kinnate Biopharma prices further upsized IPO at $20, above the upwardly revised range
nasdaq.com - December 3 at 10:28 PM
Kinnate Biopharma stock more than doubles in trading debutKinnate Biopharma stock more than doubles in trading debut
msn.com - December 3 at 10:28 PM
DateCompanyBrokerageAction
5/7/2021Vor BiopharmaB. RileyReiterated Rating
3/9/2021Vor BiopharmaBarclaysInitiated Coverage
3/8/2021Vor BiopharmaThe Goldman Sachs GroupInitiated Coverage
3/8/2021Vor BiopharmaStifel NicolausInitiated Coverage
3/8/2021Vor BiopharmaEvercore ISIInitiated Coverage
4/19/2021Connect BiopharmaSVB LeerinkInitiated Coverage
4/19/2021Connect BiopharmaJefferies Financial GroupInitiated Coverage
4/13/2021Connect BiopharmaPiper SandlerInitiated Coverage
3/8/2021Bolt BiotherapeuticsMorgan StanleyInitiated Coverage
3/8/2021Bolt BiotherapeuticsGuggenheimInitiated Coverage
4/15/2021Oxford BiomedicaLiberum CapitalReiterated Rating
7/31/2020Oxford BiomedicaPeel HuntReiterated Rating
12/28/2020Kinnate BiopharmaWedbushInitiated Coverage
(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.